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The two types ofplasminogen activator (PA), tissue-type PA (t-PA) and urokinase-
type PA (u-PA), are serine proteases that cleave plasminogen to plasmin and are
the products of separate genes (1). t-PA, which has a high affinity for fibrin, is likely
to be the major PA involved in fibrinolysis; u-PA probably mediates extracellular
proteolytic events, such as tissue destruction and remodeling (1). With the exception
of a distinctly different but uncharacterized 52-kD PA-like species (2), evidence has
previously been presented that monocytes/macrophages produce only u-PA (3-5).
Furthermore, previous investigators have detected PA activity in the supernatants
from both unstimulated and stimulated monocytes only after inhibitors of PA ac-
tivity have been removed from the supernatants by treatment with SDS (3), by sepa-
ration on SDS-PAGE (4), or by dialysis (2). We show here for the first time that
human monocytes, when stimulated appropriately in vitro, can produce t-PA of 70
kD; this activity is detectable in culture supernatants without prior biochemical treat-
ment to remove inhibitors.
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Monocyte Isolation and Culture.
￿
As before (6), monocytes were isolated from peripheral ve-
nous blood by countercurrent centrifugal elutriation; extensive precautions were taken to
limit LPS contamination. Cell fractions containing 395% monocytes, identified by morpho-
logical criteria and by nonspecific esterase staining, were pooled and cultured for 18 h (0.8-1 .0
x 10" in 1 ml a-modified Eagle's medium containing 1% FCS (6). Where indicated, LPS
from Escherichia coli 0111:B4 (Difco Laboratories, Inc., Detroit, MI) and human rIFN-,y (Dr.
E. Hochuli, Hoffmann-La Roche, Basel, Switzerland) were added at 100 ng/ml and 100 U/ml,
respectively. To terminate the cultures, the supernatants were centrifuged to remove nonad-
herent cells; adherent and nonadherent cells were pooled, washed, and lysed with 0.2% Triton
X-100 in PBS.
Assayfor PA Activity.
￿
Monocyte supernatants or lysates (50 1.1) and human plasminogen
(0.8 hg), dissolved in 100 p,l 0.1 M Tris-HCI, pH 8 .1, were added to 0.28-cm2 wells previ-
ously coated with ['25I]fibrin (7). After 2-3 h, soluble [ 251]fibrin degradation products were
measured. PA activity was expressed according to the activity of u-PA standards (Leo Phar-
maceutical Products, Denmark). Monocyte-derived plasminogen-independent fibrinolysic
activity was always 45% of the plasminogen-dependent activity.
IgGs.
￿
IgGs were isolated from rabbit antisera to human u-PA and to human t-PA (Dr.
W.-D. Schleuning, CHUV, Lausanne, Switzerland) by standard methods using protein
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A-Sepharose CL-4B (Pharmacia Fine Chemicals, Uppsala, Sweden). The mouse myeloma
IgG, HOPCY (Dr. A. Burgess, Ludwig Institute for Cancer Research, Melbourne), was used
as an irrelevant antibody. Culture supernatants, cell lysates, or PA standards (u-PA as above,
t-PA as a culture supernatant from the MM138 melanoma cell line [8, 91) (Dr. R. Whitehead,
Ludwig Institute for Cancer Research, Melbourne) (0.2 IU/ml) were incubated with IgGs
(1 ttg/ml final concentration) for 1 h at 37°C before assay of residual PA activity. In the im-
munoprecipitation experiments, protein A-Sepharose CL-4B was used (4).
SDS-casein Zymography.
￿
SDS-PAGE zymography was carried out essentially as published
(10). The resolving gel (10%) contained casein (2 mg/ml; Sigma Chemical Co., St. Louis,
MO) and human plasminogen (6 jig/ml). After electrophoresis and washing, the gels were
stained as previously described (10).
Detection oft-PA mRNA.
￿
Total monocyte RNA (11) (5 lAg/lane ofa formaldehyde-containing
1 % agarose gel) was transferred to Genescreen Plus nylon membrane (DuPont Co., Wil-
mington, DE) and hybridized overnight at 60°C in a standard hybridization buffer (7) con-
taining >2 x 106 cpm/ml of 32P-labeled t-PA cRNA. The cRNA probe was prepared from
a human t-PA-containing pGEM-4 blue vector (Promega Biotec, Madison, WI) (12). After
hybridization, the filter was washed three times with 2 x SSC before treatment with 1 Jig/ml
RNase A (Boehringer Mannheim Biochemicals, Mannheim, FRG) for 20 min at 37°C.
Results
PA Activity in Monocyte Culture Supernatants.
￿
As previously reported for unstimu-
lated cells (2-5), PA activity was not detected in the supernatants of untreated human
monocytes. However, culture with LPS (100 ng/ml) resulted in measurable PA ac-
tivities in the supernatants ofmonocytes from 90 % ofdonors examined (Fig. 1 ; after
18 h, mean PA activity ± SEM = 0.14 ± 0.03 IU/106 cells). Levels of LPS as low
as 10 ng/ml were sufficient to stimulate the expression of PA activity by monocytes
from many individuals. IFN-1' (100 U/ml) did not stimulate monocytes for detect-
able PA activity, but consistently synergized with LPS to increase PA activity ofmono-
cytes from all donors (Fig. 1; after 18 h, mean PA activity ± SEM = 0.43 t 0.08
IU/106 cells). PA activity could be detected just 6 h after adding LPS with IFN-,y.
Characterization ofPA activity in Monocyte Culture Supernatants.
￿
All ofthe PA activity
LPS LPS
-IF"
FIGURE 1.
￿
PA activity in the supernatants of cultured human
monocytes from 29 donors. Monocytes were cultured for 18 h with
LPS f IFN-y, and PA activity was assayed as described in
Materials and Methods. Each point represents the mean PA ac-
tivity detected in supernatants from triplicate monocyte cultures.
The activity is expressed according to the number ofcells initially
plated; no significant change was seen in the number of mono-
cytes in any treatment group after 18 h in culture.HART ET AL .
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FIGURE 2 .
￿
Immunological characterization of the
PA activity in monocyte culture supernatants . PA
standardsand culture supernatants from monocytes
incubated for 18 h with LPSor with LPS, + IFN-y
(pooled aliquots from duplicate cultures) were treated
with HOPCYIgG, anti-u-PA IgG, or anti-t-PA IgG,
as described in Materials and Methods . Mean ±
SEM (n = 3) .
detected in the monocyte culture supernatants was blocked by anti-t-PA IgG but
not by anti-u-PA IgG (Fig. 2) . By SDS-casein zymography, a technique that deter-
mines the apparent molecular weight ofPA and that can also detect PA in the pres-
ence of inhibitors (4, 10), a band of 52 kD corresponding to the molecular weight
ofu-PA was seen from both unstimulated and stimulated monocytes (Fig . 3 A, lanes
4-7) . This result agreed with previous studies (3, 4) . However, unlike the previous
FIGURE 3 .
￿
Characterization ofmonocyte PA
activity by SDS-casein zymography. Clear
bands of lysis appeared where PA had con-
verted plasminogen to plasmin, which then
degraded the casein . The main caseinolytic
bandsforu-PA and t-PA standards(0.2 IU/ml)
were detected at 52 and 70 kD, respectively,
as defined bythe migration pattern oflowmo-
lecular weight markers (Pharmacia Fine
Chemicals) . For the u-PA standard, but not
the monocyte supernatants or lysates, a 36-
kD breakdown product (4)was detected . (A)
Supernatants from monocytes ofa represen-
tative donor after culture for 18 h . Lane 1,
u-PA standard ; lane 2, t-PA standard ; lane
3, medium used for monocyte culture sup-
plemented with 1% FCS(showing the casein-
olytic bands due to high molecular weight
serumcomponents) ; lane 4, pooled superna-
tants from duplicate culturesofcontrol mono-
cytes ; lanes 5-7, pooled supernatants from
duplicate cultures of monocytes incubated
with IFN-y, LPS, and LPS + IFN-y, respec-
tively. (B) Identification ofthe lytic species in
amonocyte culture supernatant by immuno-
precipitation . Lane 1, u-PA standard; lane 2,
t-PA standard ; lane 3, pooled supernatant
from monocytes stimulated with LPS and
IFN-y before incubation with IgG ; lanes 4and
5, unprecipitated material and pellet, respectively, after incubationwith anti-t-PA IgG ; lane 6, unprecipi-
tated material after incubation with anti-u-PA IgG ; lane 7, unprecipitated material after incubation
withHOPCYIgG . (C) Characterization ofPA activity in monocyte lysates . Lane 1, control monocytes
incubated for 18 h ; lanes 2-4, monocytes incubated for 18 h with IFN-y, LPS, and LPS + IFN-'Y,
respectively ; lane 5, u-PA standard; lane 6, t-PA standard.1512
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FIGURE 4 .
￿
Expression of t-PA mRNA in human
monocytes . Cultures were with no added stimuli (C),
with LPS, or with LPS and IFN-y . Northern anal-
ysis was carried out as described in Materials and
Methods . Levels ofmRNA in t-PA-producing mela-
noma cells, MM170 (8, 9), were also examined .
studies, a 70-kD band migrating in a manner characteristic of the t-PA standard
was found, as well as the u-PA band in the supernatants of monocytes incubated
with either LPS or LPS with IFN-y (Fig. 3 A, lanes 6and 7) . By precipitation with
anti-t-PA IgG, thisband ofPA activitywasconfirmed as t-PA (Fig. 3 B, lanes 4 and 5) .
Monocyte-associatedPA Activity.
￿
PA activities in monocyte lysateswere consistently
<0.01 IU/10 6 cells and hence were considerably lower than those found in culture
supernatants (Fig . 1) . When mean cell-associated PA activities were calculated for
nine cell donors, there were no significant differences between control cells and cells
treated with IFN-'y or with LPS t IFN-y. Regardless of the treatment protocol,
this cell-associated PA activity was of the u-PA type, based on zymography (Fig .
3C) and on its removal by incubation with anti-u-PA IgG (data not shown) .
Detection ofMonocyte t-PA mRNA .
￿
Northern analysis showed the presence of t-PA
mRNA in monocytes treated with LPS and even greater levels in cells incubated
with LPS and IFN-y together (Fig . 4) . ActinomycinD (2 hg/ml; Sigma Chemical
Co.) inhibited the appearance ofmonocyte t-PA activity, suggestingenhanced t-PA
gene transcription. Northern blots probed with a 12p-labeled u-PA cDNA (7)
showed that LPS, but not IFN-y, elevated the basal u-PA mRNA level ; IFN-y did
not synergise with LPS for further enhancement of the LPS-induced u-PAmRNA
(data not shown) .
Discussion
We report here that human monocytes can secrete into the culture medium a spe-
cies ofPA that is readily detected without prior electrophoresis, SDS treatment, or
dialysis . This PA activity was identified immunologically to be t-PA (Fig . 2) . SDS-
casein zymography revealed two bands ofPA activity, corresponding to enzymes
of 52 and 70 kD, confirming the production ofu-PA (as previously reported) (3-5)
and t-PA (previously unreported), respectively (Fig . 3) . Monocytes secretepredom-
inantly PA inhibitor type 2, which has been reported to inhibit preferentially u-PA
(13), andwhich couldaccount forthedetection oft-PA but not u-PA activity in mono-
cyte culture supernatants (Fig . 2) . Detection of t-PA mRNA was consistent with
the biochemical and immunological characterization of t-PA produced by human
monocytes . Deliberate addition oflymphocytes to thehighly purified monocyte cul-
tures did not increase the t-PA activity, suggesting that the t-PA detected was indeed
a monocyte product . LPS was necessary in ourstudies to induce t-PA activity; how-
ever, there may be other biological stimuli that similarly enhance the expression of
monocyte t-PA activity.HART ET AL.
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It is significant that t-PA activity was observed even in SDS-casein gels where fibrin,
which potentiates t-PA activity (1), is absent; the casein in these gels is more selective
for u-PA (14). Cell-associated PA activity was of the u-PA type (Fig. 3 C) and sug-
gested that t-PA is secreted rather than stored by stimulated monocytes or that stored
t-PA cannot be detected until it is released from the cells. Precise determination
of the relative amounts of intracellular and extracellular PA is difficult because of
the complicating influences of monocyte-derived PA inhibitor(s) (4, 13), of u-PA
receptors on the monocyte surface (1), and of the differential enhancement of t-PA
and u-PA activities by fibrin and casein (1, 14), respectively.
Fibrin deposition occurs at sites of tissue damage, including chronic inflamma-
tory lesions, and the stimulation ofmonocytes to express t-PA activity could provide
a mechanism to hasten dissolution of fibrin at such sites. In addition, there is evi-
dence for a significant cellular-phase component of blood fibrinolytic activity both
under normal resting conditions, and in physiologically or pharmacologically al-
tered states (15). We suggest the possible involvement of monocytes through their
expression of t-PA activity.
The clinical use of t-PA as a thrombolytic agent for the treatment of myocardial
infarcts, for example, is becoming established (16). However, because of its short
half-life, large quantities of t-PA are administered intravenously over several hours
and this may cause unwanted bleeding (16). Pharmacological induction oflocal t-PA
activity at a thrombus might be extremely useful, and controlled stimulation of local
monocytes for t-PA activity could be one approach. In this context, it should be noted
that since foam cells in atherosclerotic plaques are derived from circulating mono-
cytes (17), the level of t-PA activity produced by these monocytes/foam cells may
determine in part the persistence or resolution of the fibrin in early lesions.
Summary
Evidence has previously been presented that monocytes and macrophages pro-
duce urokinase-type plasminogen activator. We have shown for the first time that
human monocytes, when stimulated appropriately in vitro, can produce tissue type-
plasminogen activator (t-PA) of 70 kD. Detection oft-PA mRNA was consistent with
the biochemical and immunological characterization of t-PA produced by human
monocytes.
Receivedfor publication 5 December 1988 and in revisedform 17January 1989.
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